Rhabdomyolysis due to warfarin and atorvastatin combination therapy in a patient with ischemic heart disease: (A drug interaction)

被引:1
作者
Soliemanabad, Saeed Kargar [1 ]
Rasouli, Kimia [1 ]
Zakariaei, Zakaria [2 ,3 ]
Soleymani, Mostafa [3 ]
Aliabadi, Parastoo Karimi [4 ]
机构
[1] Mazandaran Univ Med Sci, Student Res Comm, Sari, Iran
[2] Mazandaran Univ Med Sci, Imam Khomeini Hosp, Toxoplasmosis Res Ctr, Toxicol & Forens Med Div, POB 48166-33131, Sari, Iran
[3] Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Iranian Natl Registry Ctr Lophomoniasis & Toxopla, Communicable Dis Inst, Sari, Iran
[4] Mazandaran Univ Med Sci, Diabet Res Ctr, Dept Family Med, Sari, Iran
来源
ANNALS OF MEDICINE AND SURGERY | 2022年 / 75卷
关键词
Atorvastatin; Warfarin; Drug interaction; Rhabdomyolysis; ACUTE KIDNEY INJURY;
D O I
10.1016/j.amsu.2022.103384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Although atorvastatin has serious adverse effects, including hepatotoxicity and myopathy, it can cause drug interactions and side effects such as rhabdomyolysis and acute kidney injury, especially when combined with warfarin, which uses the same enzyme pathway for metabolism. Case presentation: We describe a 66-year-old man with a history of ischemic heart disease who developed renal complications and rhabdomyolysis after concomitant use of atorvastatin and warfarin. Discussion: Statins reduce serum LDL cholesterol levels significantly. It is a safe and cost-effective medicine used in the treatment of DLP as well as the primary and secondary prevention of CAD, atherosclerosis, myocardial infarction, and stroke. Despite their benefits, statins can cause side effects in various organs of the body, including the gastrointestinal tract, CNS, liver, and kidneys. Conclusion: Statins are widely prescribed to patients with cardiovascular problems. Therefore, clinicians should pay attention to the patient's medical history, current prescribed doses, and drug interactions when adding new drugs or adjusting existing drugs.
引用
收藏
页数:3
相关论文
共 17 条
  • [1] The SCARE 2018 statement: Updating consensus Surgical CAse REport (SCARE) guidelines
    Agha, Riaz A.
    Borrelli, Mimi R.
    Farwana, Reem
    Koshy, Kiron
    Fowler, Alexander J.
    Orgill, Dennis P.
    Zhu, Hongyi
    Alsawadi, Abdulrahman
    Noureldin, Ashraf
    Rao, Ashwini
    Enam, Ather
    Thoma, Achilleas
    Bashashati, Mohammad
    Vasudevan, Baskaran
    Beamish, Andrew
    Challacombe, Ben
    De Wilde, Rudy Leon
    Machado-Aranda, David
    Laskin, Daniel
    Muzumdar, Dattatraya
    D'cruz, Anil
    Manning, Todd
    Healy, Donagh
    Pagano, Duilio
    Goel, Prabudh
    Ranganathan, Priya
    Pai, Prathamesh S.
    Raja, Shahzad
    Athe, M. Hammad
    Kadioazlu, Huseyin
    Nixon, Iain
    Mukherjee, Indraneil
    Gomez Riva, Juan
    Raveendran, Kandiah
    Derbyshire, Laura
    Valmasoni, Michele
    Chalkoo, Mushtaq
    Raison, Nicholas
    Muensterer, Oliver
    Bradley, Patrick
    Roberto, Coppola
    Afifi, Raafat
    Rosin, David
    Klappenbach, Roberto
    Wynn, Rolf
    Giordano, Salvatore
    Basu, Somprakas
    Surani, Salim
    Suman, Paritosh
    Thorat, Mangesh
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2018, 60 : 132 - 136
  • [2] Potential statin drug interactions in elderly patients: a review
    Damiani, Isabella
    Corsini, Alberto
    Bellosta, Stefano
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (12) : 1133 - 1145
  • [3] Drug-drug interactions between vitamin K antagonists and statins: a systematic review
    Engell, Anna E.
    Svendsen, Andreas L. O.
    Lind, Bent S.
    Stage, Tore Bjerregaard
    Hellfritzsch, Maja
    Pottegard, Anton
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (10) : 1435 - 1441
  • [4] Drug-drug interaction between warfarin and statins: A Danish cohort study
    Engell, Anna E.
    Svendsen, Andreas L. O.
    Lind, Bent S.
    Andersen, Christen L.
    Andersen, John S.
    Willadsen, Tora G.
    Persson, Frederik
    Pottegard, Anton
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (02) : 694 - 699
  • [5] Rhabdomyolysis-Associated Acute Kidney Injury
    Esposito, Pasquale
    Estienne, Luca
    Serpieri, Nicoletta
    Ronchi, Dario
    Comi, Giacomo P.
    Moggio, Maurizio
    Peverelli, Lorenzo
    Bianzina, Stefania
    Rampino, Teresa
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2018, 71 (06) : XII - XIV
  • [6] Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling
    Li, Size
    Yu, Yiqun
    Jin, Zhiping
    Dai, Yu
    Lin, Haishu
    Jiao, Zheng
    Ma, Guo
    Cai, Weimin
    Han, Bing
    Xiang, Xiaoqiang
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 119
  • [7] Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin
    MacKay, J. W.
    Fenech, M. E.
    Myint, K. S.
    [J]. BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (02) : 106 - 107
  • [8] Dyslipidemia
    Mancini, G. B. John
    Hegele, Robert A.
    Leiter, Lawrence A.
    [J]. CANADIAN JOURNAL OF DIABETES, 2018, 42 : S178 - S185
  • [9] Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia
    Maxwell, Whitney D.
    Ramsey, Laura B.
    Johnson, Samuel G.
    Moore, Kate G.
    Shtutman, Michael
    Schoonover, John H.
    Kawaguchi-Suzuki, Marina
    [J]. PHARMACOTHERAPY, 2017, 37 (09): : 1172 - 1190
  • [10] Statin-Induced Rhabdomyolysis, Acute Kidney Injury, and Hepatitis Leading to Death
    Mohamed, Mouhand F. H.
    Salameh, Omar K.
    Saeed, Abazar A. M.
    [J]. AMERICAN JOURNAL OF CASE REPORTS, 2019, 20 : 709 - 712